# Motixafortide (Aphexda)

> CXCR4 antagonist peptide that mobilizes stem cells for autologous transplant in multiple myeloma.

Source: https://peptides.cafe/peptide/motixafortide
Category: CXCR4 Antagonist · Hematology
Tag: FDA-Approved · Oncology

## Mechanism
A long-acting synthetic peptide antagonist of the CXCR4 chemokine receptor. Disrupts the CXCR4/CXCL12 axis anchoring hematopoietic stem cells in the bone marrow, releasing them into circulation for collection. Used with G-CSF.

## Research areas
- Stem cell mobilization for autologous transplant in multiple myeloma

## Common research protocols
- Mobilization regimen: Single SC dose given with G-CSF before apheresis.

## Study summaries
- "GENESIS phase 3 trial of motixafortide + G-CSF" — Nature Medicine (2023): Higher proportion of patients collected ≥6×10^6 CD34+ cells/kg in ≤2 apheresis sessions vs G-CSF alone.

## Considerations
- FDA-approved September 2023.
- Common side effects: injection-site reactions, flushing, pruritus.
- Risk of hypersensitivity / anaphylactoid reactions.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.